Search

Your search keyword '"Roghmann F"' showing total 425 results

Search Constraints

Start Over You searched for: Author "Roghmann F" Remove constraint Author: "Roghmann F"
425 results on '"Roghmann F"'

Search Results

3. Breaking boundaries: Exploring extended pembrolizumab in first-line treatment of renal cell carcinoma with axitinib-pembrolizumab combination

4. First safety and efficacy results of the TAR-210 erdafitinib intravesical delivery system in patients with non–muscle-invasive bladder cancer with select FGFR alterations

6. Results from the prospective randomized UroFollow trial comparing marker-guided vs. cystoscopy-based standard follow-up in patients with low/intermediate risk bladder cancer

9. EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees

11. Is there evidence for a close connection between side of intravesical tumor location and ipsilateral lymphatic spread in lymph node-positive bladder cancer patients at radical cystectomy? Results of the PROMETRICS 2011 database

12. Impact of photodynamic diagnosis-assisted transurethral resection of bladder tumors on the prognostic outcome after radical cystectomy: results from PROMETRICS 2011

14. 1759P Enfortumab vedotin in metastatic urothelial carcinoma: Retrospective multicentre patient cohort

17. Komplikationen in der frühen Rehabilitationsphase nach radikaler Zystektomie: Ein Vergleich zwischen Ileum Conduit und Neoblase

18. Versorgungsforschung zum Outcome von Patienten nach radikaler Zystektomie

19. Harnableitungspräferenz-Index (HARPI) als neues Instrument zur Unterstützung der Partizipativen Entscheidung bei der Wahl der Harnableitung

20. Die frühe longitudinale CRP-Kinetik sagt das Ansprechen gegenüber Anti-PD-(L)1-Immuncheckpoint-Blockade im metastasiertem Urothelkarzinom voraus

21. Die Expression des Enfortumab Vedotin Zielproteins Nectin-4 nimmt während der Metastasierung des Urothelkarzinoms stark ab

22. Prospektive Versorgungsforschung zum Outcome nach radikaler Zystektomie

23. Vorhersage der Tumorpersistenz in der Re-TUR-B durch den Xpert® Bladder Cancer Monitor - Ergebnisse einer prospektiven multizentrischen Studie (MoniTURB Trial)

25. Objektive Messung der lokalen Tumorlast bei Patienten mit Blasentumoren zur Pr��diktion des Tumorstadiums ��� wie messen wir am besten?

27. EAU-ESMO consensus statements on the management of advanced and variant bladder cancer

30. Oncological and safety profiles in patients undergoing simultaneous transurethral resection of bladder tumor and prostate: Results from a large multicenter international collaboration

31. P121 - Selecting the best candidates for cisplatin-based adjuvant chemotherapy after radical cystectomy in patients with pN+ bladder cancer

32. A randomized, double-blind, placebo-controlled, phase 3 trial of infigratinib as adjuvant therapy in patients with invasive urothelial carcinoma harboring susceptible FGFR3 genetic alterations: PROOF 302

33. Selecting the best candidates for cisplatin-based adjuvant chemotherapy after radical cystectomy in patients with pN+ bladder cancer

34. Selecting the best candidates for cisplatin-based adjuvant chemotherapy after radical cystectomy in pN+ bladder cancer patients

36. Komplikationen nach radikaler Zystektomie in der frühen Rehabilitationsphase: Ein Vergleich zwischen Ileumconduit und orthotoper Neoblasenanlage

38. LBA104 First safety and efficacy results of the TAR-210 erdafitinib (erda) intravesical delivery system in patients (pts) with non–muscle-invasive bladder cancer (NMIBC) with select FGFR alterations (alt)

40. Selecting the best candidates for platinum-based adjuvant chemotherapy after radical cystectomy in pN+ bladder cancer patients

42. Evaluation präoperativer Prädiktoren für einen positiven Resektionsstatus bei radikaler Prostatektomie

43. Einfluss der Operationstechnik (offen/Roboter-assistiert) auf funktionelle Ergebnisse nach radikaler Prostatektomie bei 'high-volume' Operateuren

45. Corrigendum to ‘EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees’ [European Urology 77 (2020) 223–250](S0302283819307638)(10.1016/j.eururo.2019.09.035)

46. EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort†: Under the Auspices of the EAU-ESMO Guidelines Committees

47. Randomized controlled multicentre study of albumin replacement therapy in septic shock (ARISS): protocol for a randomized controlled trial

48. Défaut d’adoption de l’instillation intravésicale postopératoire précoce de chimiothérapie après néphro-urétérectomie totale

49. Impact of residual microscopial evidence of prostate cancer at second tumor resection on biochemical recurrence after radical prostatectomy

50. Adjuvant chemotherapy is ineffective in patients with bladder cancer and variant histology treated with radical cystectomy

Catalog

Books, media, physical & digital resources